These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 39127273)
1. Peptidylarginine deiminase (PAD): A promising target for chronic diseases treatment. Mansouri P; Mansouri P; Behmard E; Najafipour S; Kouhpayeh SA; Farjadfar A Int J Biol Macromol; 2024 Oct; 278(Pt 3):134576. PubMed ID: 39127273 [TBL] [Abstract][Full Text] [Related]
2. Applicability of Small-Molecule Inhibitors in the Study of Peptidyl Arginine Deiminase 2 (PAD2) and PAD4. Martín Monreal MT; Rebak AS; Massarenti L; Mondal S; Šenolt L; Ødum N; Nielsen ML; Thompson PR; Nielsen CH; Damgaard D Front Immunol; 2021; 12():716250. PubMed ID: 34737738 [TBL] [Abstract][Full Text] [Related]
3. Protein Arginine Deiminases (PADs): Biochemistry and Chemical Biology of Protein Citrullination. Mondal S; Thompson PR Acc Chem Res; 2019 Mar; 52(3):818-832. PubMed ID: 30844238 [TBL] [Abstract][Full Text] [Related]
4. PAD enzymes in rheumatoid arthritis: pathogenic effectors and autoimmune targets. Curran AM; Naik P; Giles JT; Darrah E Nat Rev Rheumatol; 2020 Jun; 16(6):301-315. PubMed ID: 32341463 [TBL] [Abstract][Full Text] [Related]
5. Iguratimod dose dependently inhibits the expression of citrullinated proteins and peptidylarginine deiminases 2 and 4 in neutrophils from rheumatoid arthritis patients. Li B; Li P; Bi L Clin Rheumatol; 2020 Mar; 39(3):899-907. PubMed ID: 31758423 [TBL] [Abstract][Full Text] [Related]
6. Structures of human peptidylarginine deiminase type III provide insights into substrate recognition and inhibitor design. Funabashi K; Sawata M; Nagai A; Akimoto M; Mashimo R; Takahara H; Kizawa K; Thompson PR; Ite K; Kitanishi K; Unno M Arch Biochem Biophys; 2021 Sep; 708():108911. PubMed ID: 33971157 [TBL] [Abstract][Full Text] [Related]
7. Protein Citrullination by Peptidyl Arginine Deiminase/Arginine Deiminase Homologs in Members of the Human Microbiota and Its Recognition by Anti-Citrullinated Protein Antibodies. Pérez-Pérez ME; Nieto-Torres E; Bollain-Y-Goytia JJ; Delgadillo-Ruíz L Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791230 [TBL] [Abstract][Full Text] [Related]
8. Peptidylarginine Deiminase Inhibitor Application, Using Cl-Amidine, PAD2, PAD3 and PAD4 Isozyme-Specific Inhibitors in Pancreatic Cancer Cells, Reveals Roles for PAD2 and PAD3 in Cancer Invasion and Modulation of Extracellular Vesicle Signatures. Uysal-Onganer P; D'Alessio S; Mortoglou M; Kraev I; Lange S Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33573274 [TBL] [Abstract][Full Text] [Related]
9. The roles of PAD2- and PAD4-mediated protein citrullination catalysis in cancers. Wang Y; Chen R; Gan Y; Ying S Int J Cancer; 2021 Jan; 148(2):267-276. PubMed ID: 33459350 [TBL] [Abstract][Full Text] [Related]
10. Revamped role for approved drug: integrative computational and biophysical analysis of saquinavir's peptidyl arginine deiminase 4 inhibition for rheumatoid arthritis. Thirugnanasambandham I; Jupudi S; Roychowdhury P; Karri VVSR; Madhunapantula SRV; Singh SK; Subramaniyan V; Kuppusamy G Biochem J; 2024 Oct; 481(20):1379-1393. PubMed ID: 39312210 [TBL] [Abstract][Full Text] [Related]
11. Discovery of Novel Potential Reversible Peptidyl Arginine Deiminase Inhibitor. Aliko A; Kamińska M; Falkowski K; Bielecka E; Benedyk-Machaczka M; Malicki S; Kozieł J; Wong A; Bryzek D; Kantyka T; Mydel P Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31052493 [TBL] [Abstract][Full Text] [Related]
12. Citrulline Not a Major Determinant in the Recognition of Peptidylarginine Deiminase 2 and 4 by Autoantibodies in Rheumatoid Arthritis. Darrah E; Davis RL; Curran AM; Naik P; Chen R; Na CH; Giles JT; Andrade F Arthritis Rheumatol; 2020 Sep; 72(9):1476-1482. PubMed ID: 32255561 [TBL] [Abstract][Full Text] [Related]
13. Peptidylarginine deiminase 2, 3 and 4 have distinct specificities against cellular substrates: novel insights into autoantigen selection in rheumatoid arthritis. Darrah E; Rosen A; Giles JT; Andrade F Ann Rheum Dis; 2012 Jan; 71(1):92-8. PubMed ID: 21859690 [TBL] [Abstract][Full Text] [Related]
14. Generation of Distinct Patterns of Rheumatoid Arthritis Autoantigens by Peptidylarginine Deiminase Types 2 and 4 During Perforin-Induced Cell Damage. Romero V; Darrah E; Andrade F Arthritis Rheumatol; 2020 Jun; 72(6):912-918. PubMed ID: 31876120 [TBL] [Abstract][Full Text] [Related]
16. Identification of potential autoantigens in anti-CCP-positive and anti-CCP-negative rheumatoid arthritis using citrulline-specific protein arrays. Poulsen TBG; Damgaard D; Jørgensen MM; Senolt L; Blackburn JM; Nielsen CH; Stensballe A Sci Rep; 2021 Aug; 11(1):17300. PubMed ID: 34453079 [TBL] [Abstract][Full Text] [Related]
17. Relative efficiencies of peptidylarginine deiminase 2 and 4 in generating target sites for anti-citrullinated protein antibodies in fibrinogen, alpha-enolase and histone H3. Damgaard D; Bawadekar M; Senolt L; Stensballe A; Shelef MA; Nielsen CH PLoS One; 2018; 13(8):e0203214. PubMed ID: 30161253 [TBL] [Abstract][Full Text] [Related]
18. Release of Active Peptidyl Arginine Deiminases by Neutrophils Can Explain Production of Extracellular Citrullinated Autoantigens in Rheumatoid Arthritis Synovial Fluid. Spengler J; Lugonja B; Ytterberg AJ; Zubarev RA; Creese AJ; Pearson MJ; Grant MM; Milward M; Lundberg K; Buckley CD; Filer A; Raza K; Cooper PR; Chapple IL; Scheel-Toellner D Arthritis Rheumatol; 2015 Dec; 67(12):3135-45. PubMed ID: 26245941 [TBL] [Abstract][Full Text] [Related]
19. Quantitative evaluation of citrullinated fibrinogen for detection of neutrophil extracellular traps. Sue T; Ichikawa T; Hattori S; Otani H; Fujimura S; Higuchi T; Okumura N; Higuchi Y Immunol Res; 2024 Jun; 72(3):409-417. PubMed ID: 38087184 [TBL] [Abstract][Full Text] [Related]
20. Peptidylarginine deiminases 4 as a promising target in drug discovery. Yang C; Dong ZZ; Zhang J; Teng D; Luo X; Li D; Zhou Y Eur J Med Chem; 2021 Dec; 226():113840. PubMed ID: 34520958 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]